← Back to headlines
Mimedx Forecasts 2026 Net Sales Amid Cost Cuts and Reimbursement Changes
Mimedx expects net sales between $260 million and $290 million by 2026, alongside $40 million in cost reductions and adjustments due to disruptions in wound care reimbursement.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
